Drug delivery

Bexson Biomedical and Stevanato Group Awarded PDA Drug Delivery Innovation Award

Retrieved on: 
Thursday, October 20, 2022
Quality of life, CA, Parenteral Drug Association, NYSE, Biotechnology, Patient, Program, Ketamine, Group, PDA, Opioid, Stevanato Group, Drug delivery, Biomedicine, Solution, Engineering, Leadership, Fine chemical, Pharmaceutical industry

SANTA BARBARA, Calif., Oct. 19, 2022 /PRNewswire/ -- Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced Bexson and Stevanato Group (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, have been jointly awarded the Parenteral Drug Association's (PDA) 2022 Drug Delivery Innovation Partnership Award.

Key Points: 
  • SANTA BARBARA, Calif., Oct. 19, 2022 /PRNewswire/ -- Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced Bexson and Stevanato Group (NYSE: STVN), a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life sciences industries, have been jointly awarded the Parenteral Drug Association's (PDA) 2022 Drug Delivery Innovation Partnership Award.
  • This award recognizes the collaboration between Bexson Biomedical and Stevanato Group to optimize Stevanato Group's innovative wearable device On Body Delivery System (OBDS) with Bexson's formulation technology.
  • "It is an honor for Stevanato Group to receive this award, which recognizes the long collaboration with Bexson," adds Stevanato Group's, Paolo Golfetto.
  • Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries.

Global Vietnam Generic Drugs Market Report 2022: Quickly Developing National Pharmaceutical Industry Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, September 30, 2022
Health, Pharmaceutical, Molecule, Mode, Drug delivery, Drug, Name, Prescription, Application, Growth, Market share, Diabetes, Route of administration, Oral, Cardiovascular disease, Form, Conditional sentence, Pharmaceutical industry

Vietnam generic drugs market is projected to witness growth at a significant rate during the forecast period, 2023-2027.

Key Points: 
  • Vietnam generic drugs market is projected to witness growth at a significant rate during the forecast period, 2023-2027.
  • The market growth can be attributed to the rising demand for affordable drugs and the growing need for over-the-counter drugs against branded drugs.
  • One of the main factors boosting the growth of the Vietnam generic drugs market in the coming five years is the nation's quickly developing pharmaceutical industry.
  • In this report, Vietnam generic drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
    Vietnam Generic Drugs Market, By Mode of Drug Delivery:

PDA Announces Nearly 100 Exhibitors at the 19th Universe of Pre-Filled Syringes and Injection Devices Conference

Retrieved on: 
Thursday, September 29, 2022
Universe, PDA, Drug delivery, Exhibition, Parenteral Drug Association, University residence hall network, Industry, Syringe, Patient, Organization, Technology, ANSI, Rise Up (conference), Science, UPS, Conference, Education, EMA, Pharmaceutical industry, EU

BETHESDA, Md., Sept. 29, 2022 /PRNewswire-PRWeb/ -- The Parenteral Drug Association, Inc. (PDA), today announced that 96 exhibitors will present their technologies at the first in-person Universe of Pre-Filled Syringes and Injection Devices (UPS) Conference since 2019. It will be held in Palm Springs, Ca., 18-19 Oct. The 2020 and 2021 conferences were held as virtual events.

Key Points: 
  • BETHESDA, Md., Sept. 29, 2022 /PRNewswire-PRWeb/ -- The Parenteral Drug Association, Inc. (PDA), today announced that 96 exhibitors will present their technologies at the first in-person Universe of Pre-Filled Syringes and Injection Devices (UPS) Conference since 2019.
  • "The organizing committee is delighted to welcome delegates back to the PDA Universe of Pre-Filled Syringes and Injection Devices Conference," said Mathias Romacker, committee co-chair and executive advisor, Kymanox.
  • "This year we are finally back to meet in person and so many new topics are there to be discussed.
  • Continued advances in materials of construction, manufacturing processes, injection processes and safety devices, and other technology improvements create a dynamic environment in the drug delivery device arena.

India Generic Drugs Market Research Report 2022: Small Molecule Generics v/s Biosimilars - Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 3, 2022
Health, Pharmaceutical, Molecule, Cardiovascular disease, Mode, Bolt-on acquisition, Diabetes, Form, Patient, Conditional sentence, Forecast, Application, Oral, Prevalence, Technology, USD, CAGR, Market share, Competition, Awareness, Route of administration, Drug delivery, Generic drug, Medical device, Health insurance

In developing countries like India, government bodies and other regulatory bodies have encouraged manufacturers to launch effective generic drugs supporting market growth.

Key Points: 
  • In developing countries like India, government bodies and other regulatory bodies have encouraged manufacturers to launch effective generic drugs supporting market growth.
  • To analyze the historical growth of the market size of the Indian Generic Drugs Market from 2018 to 2021.
  • To estimate and forecast the market size of the Indian Generic Drugs Market from 2023 to 2028 and growth rate until 2028.
  • To identify key sustainable strategies adopted by the market players in the Indian Generic Drugs Market.

Global Drug Delivery Devices Market Report 2022: Featuring Key Players F. Hoffmann-La Roche, 3M Company, Pfizer & Baxter International - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 20, 2022
Pharmaceutical, Health, Medical Devices, WHO, Midsayap Diagnostic Center and Hospital, Diabetes, Asia-Pacific, MDSAP, World Health Organization, Conditional sentence, Moyamoya disease, Cancer, Hospital, IHD, Drug delivery, Ophthalmic drug administration, Degenerative disease, Route of administration, Stroke, Death, Lists of countries and territories, Health care, Growth, Administration, Prevalence, Medical device, Pharmaceutical industry

The "Global Drug Delivery Devices Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Drug Delivery Devices Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • Asia Pacific was the second-largest region in the drug delivery devices market.
  • The regulatory changes related to medical devices is expected to restraint the growth of drug delivery devices market.
  • 1) By Route Of Administration: Oral Drug Delivery; Injectable Drug Delivery; Topical Drug Delivery; Ocular Drug Delivery; Pulmonary Drug Delivery; Nasal Drug Delivery; Transmucosal Drug Delivery; Implantable Drug Delivery
    2) By Patient Care Setting: Hospitals; Diagnostic Centers; Ambulatory Surgery Centers/Clinics; Home Care Settings; Other Patient Care Settings

Selectis Health Provides Business Update

Retrieved on: 
Monday, July 11, 2022
Ageing, Partnership, Medicare, Health, COO, Omicron, Levin, PricewaterhouseCoopers, PulteGroup, Fürstenberg, Population, HR, CEO, Regulation S-K, Industry, Speech, Tax, Centers for Medicare & Medicaid Services, Medicaid, Center, GBCS, Michigan State University, Park Place, Nursing, Company, Baller, San Diego State University, Village, Mission statement, OTC, Accounting, Regulation, GLOBE, Drug delivery, VP, Patient, SEC, CMS, Controller, Growth, Efficiency, Rehabilitation, PC, Wayne State University Law School, Renewable energy, Audit, Health insurance, Pharmaceutical industry, Management, Medicine, Lucus

Greenwood Village, Colorado, July 11, 2022 (GLOBE NEWSWIRE) -- Selectis Health, Inc. (OTC: GBCS) ("Selectis" or the "Company") is providing a business update on its recent strategic and operational highlights through the second quarter of 2022.

Key Points: 
  • Greenwood Village, Colorado, July 11, 2022 (GLOBE NEWSWIRE) -- Selectis Health, Inc. (OTC: GBCS) ("Selectis" or the "Company")is providing a business update on its recent strategic and operational highlights through the second quarter of 2022.
  • Selectis continues to focus on staffing buildout across its facility footprint, with the goal of eliminating third-party agency staffing needs by year-end 2022.
  • With her strong financial reporting and health industry background, she has made meaningful contributions to Selectis throughout her tenure with the Company.
  • Selectis focuses on building strategic relationships with local communities in which its partnership can improve the quality of care for facility residents.

Global Drug Delivery Partnering Deals Terms and Agreements Analysis Report/Directory 2015-2022 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 10, 2022
Biotechnology, Pharmaceutical, Health, Hyperlink, Securities & Exchange Commission of Pakistan, A-Z, U.S. Securities and Exchange Commission, Mecum Dealmakers, Record, Research, Drug delivery, Agreement, Drug, Medical device, Pharmaceutical industry, Risk management

The "Global Drug Delivery Partnering Terms and Agreements 2015-2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Drug Delivery Partnering Terms and Agreements 2015-2022" report has been added to ResearchAndMarkets.com's offering.
  • The Global Drug Delivery Partnering Terms and Agreements 2015-2022 report provides comprehensive understanding and unprecedented access to the Drug Delivery partnering deals and agreements entered into by the worlds leading healthcare companies.
  • The report takes the reader through a comprehensive review Drug Delivery deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Drug Delivery partnering deals.
  • Global Drug Delivery Partnering Terms and Agreements 2015-2022 provides the reader with the following key benefits:
    Insight into terms included in a Drug Delivery partnering agreement, with real world examples
    In Global Drug Delivery Partnering Terms and Agreements 2015-2022, the available deals are listed by:

Dr. Kiana Aran and Dr. Paul Grint appointed to CRISPR QC Board of Directors

Retrieved on: 
Thursday, June 9, 2022
Technology, Biotechnology, Nanotechnology, Health, Pharmaceutical, Stem Cells, Other Science, Research, General Health, Agriculture, Genetics, Natural Resources, Science, Semiconductor, Acceleration, Board, Keck Graduate Institute, Bill, Medical diagnosis, Royal college, Agriculture, Quality control, Chinese General Hospital Colleges, Assistant professor, Knowledge, Associate, University of London, CEO, CRISPR, DNA, NIH, List of life sciences, Therapy, University, Claremont Colleges, Marie Cassidy, Patient, Technology, Infection, Woman, University of California, Berkeley, Consultant, Clinical, NJCAA National Football Championship, Mechanics, Food chain, Drug delivery, DARPA, Bill & Melinda Gates Foundation, NSF, Medical device, Pharmaceutical industry, Science, List of pathologists

On June 09, 2022, CRISPR QC has announced that Paul Grint and Dr. Kiana Aran have been appointed to the board of directors.

Key Points: 
  • On June 09, 2022, CRISPR QC has announced that Paul Grint and Dr. Kiana Aran have been appointed to the board of directors.
  • "CRISPR QCs technology is empowering scientists to put the puzzle pieces together of CRISPR editing in a way that was not before possible.
  • This insight is driving better understanding of CRISPR activity that will lead to an acceleration of game-changing gene therapies, developments in agriculture, and more," says Dr. Kiana Aran.
  • Dr. Kiana Aran is a pioneer of combining CRISPR with modern electronics.

RenovoRx to Participate in the University of Cambridge’s Academy of Therapeutic Sciences Gateway to Translation Seminar Series on June 8, 2022

Retrieved on: 
Thursday, June 2, 2022
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Pancreatic tumor, Intellectual property, University, Research, Securities Exchange Act of 1934, Survival, Drug Quality and Security Act, Forward-looking statement, Nature, Treatment, Cancer, Security (finance), U.S. Securities and Exchange Commission, Pancreatic cancer, Nasdaq, Q&A, FDA, Transplant, Patient, Technology, Cholangiocarcinoma, COVID-19, CATS, Securities Act of 1933, Industry, Medicine, Gateway, Intra, Drug delivery, Neoplasm, Safety, Terminology, Pharmaceutical industry, LAPC

Dr. Ramtin Agah, Chief Medical Officer and Co-Founder of RenovoRx, will present a seminar, Localized Intra-arterial Drug Delivery for Treatment of Solid Tumors.

Key Points: 
  • Dr. Ramtin Agah, Chief Medical Officer and Co-Founder of RenovoRx, will present a seminar, Localized Intra-arterial Drug Delivery for Treatment of Solid Tumors.
  • The seminar will be chaired by Prof. Saeb-Parsy, Professor of Transplantation at the University of Cambridge, and will be followed by a live Q&A session.
  • It is an honor to present at the upcoming Gateway to Translation Seminar Series at the University of Cambridge.
  • RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards Life Sciences Edition 2020 for its RenovoTAMP technology.

ClearPoint Neuro and Higgs Boson Health Announce Collaboration

Retrieved on: 
Tuesday, May 3, 2022
Interface (computing), COVID-19, U.S. Securities and Exchange Commission, Organizational founder, Lists of diseases, Insurance, Nasdaq, GLOBE, CNS, Brain–computer interface, Company, Patient satisfaction, Patient, App, COVID, Paper, Security (finance), Partnership, Clinical trial, FDA, Family, Therapy, Higgs boson, Particular, Duke University, Quality of life, Spine, Efficiency, Education, BCI, Solution, Drug delivery, Research, CEO, Biopsy, Growth, Patient education, Search for the Higgs boson, Medical device, Medicine, Neurosurgery, Brain, Gastroenterology

Higgs Boson is proud to partner with ClearPoint Neuro to advance targeted pharmaceutical delivery and deliver cutting-edge Brain Computer Interface (BCI) solutions.Together, we will help patients and families navigate their condition, clinical studies, procedures and stay on track for the best outcomes, said Rajeev Dharmapurikar, CEO of Higgs Boson Health.

Key Points: 
  • Higgs Boson is proud to partner with ClearPoint Neuro to advance targeted pharmaceutical delivery and deliver cutting-edge Brain Computer Interface (BCI) solutions.Together, we will help patients and families navigate their condition, clinical studies, procedures and stay on track for the best outcomes, said Rajeev Dharmapurikar, CEO of Higgs Boson Health.
  • Studies in spine surgery and breast surgery have confirmed the effectiveness of Higgs Bosons care navigation app in improving important patient-reported health outcomes.
  • Higgs Bosons partnership with ClearPoint Neuro exemplifies our shared patient-centric approach.
  • Based in Durham, NC, Higgs Boson Health partners with leading medical device companies and academic health systems.To learn more, visit www.higgsbosonhealth.com .